Pharmaceutical firms led by Eli Lilly are trying to eliminate a government panel aimed at controlling Medicare spending seven months after they supported the health-care overhaul that created it.
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
A federal audit recommends that Indiana's human services agency refund the federal government nearly $39 million it overpaid to Medicaid providers during a nine-year period.
Could nurse practitioners get a promotion in the medical field? At least one health insurer is treating them like doctors now.
Moody’s Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent expirations the drugmaker faces in coming years.
A study at the Center for Health Policy at IUPUI found that 66 cents of every dollar the state spends on services related to substance abuse goes toward health care while only 1 cent goes toward prevention or intervention.
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
The Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions, which could mean another $500 million in annual sales for Lilly, an analyst estimates.
In Utah, employers can give each of their workers a specific amount of money to apply toward health insurance. The worker then can use that money to choose from the 66 plans in the health insurance exchange.
Billboard companies spiked the cancer ad. But Citizens Gas or WellPoint might have gotten a different result.
Bill Styring, whose long, wonkish career includes analyzing health reform for Mike Pence, cried last night.
Jim Hamilton, an employee-benefits lawyer at Bose McKinney & Evans in Indianapolis, discussed the likelihood of a Republican-controlled U.S. House of Representatives changing or even outright repealing the health care reform law, formally known as the Patient Protection and Affordable Care Act.
Without an appeal, generic drugs are now poised to wipe away most of Lilly’s $750 million in annual U.S. revenue from Gemzar.
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
Warsaw-based Orthopedic implant maker Zimmer Holdings Inc. reported net income of $191.1 million, or 96 cents per share. Sales fell 1 percent to $965 million from $975.6 million.
Jan Roberts pairs numbers and nurturing—further fueled by a fight with breast cancer —to power the city's fifth largest woman-owned business.
Indiana University will no longer ask employees to fill out an online health risk assessment after more than 550 people—many anonymous—attached names to an online petition that said the plan would cause “widespread anger and disillusionment.”
A new estimate has lowered the expected cost of the federal health care overhaul to Indiana’s state government to perhaps $2.6 billion over the next decade.
